Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 3/20 | 0.35 |
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766394 | 0.87 | P2RX4 (0.34) | P2RX4RENALOX5 | |
| Hydrochloric Acid SCHEMBL6766830 | 0.85 | ALOX5 (0.33) | P2RX4RENALOX5 | |
| SCHEMBL6777657 | 0.83 | APEX1 (0.40) | — | |
| SCHEMBL5863624 | 0.82 | ALOX5 (0.35) | P2RX4ALOX5 | |
| SCHEMBL7596964 | 0.79 | P2RX4 (0.33) | P2RX4REN | |
| SCHEMBL6770322 | 0.77 | KMT2A (0.46) | — | |
| SCHEMBL5863425 | 0.77 | MTTP (0.48) | — | |
| SCHEMBL6771836 | 0.77 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL6772724 | 0.75 | RAB9A (0.42) | — | |
| SCHEMBL7599789 | 0.74 | ALOX5 (0.32) | P2RX4RENALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | MTTP, CETP, CPT1A | P2RX4 1433/4885REN 687/4885ALOX5 2867/4885 |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | P2RX4 2084/4885REN 1962/4885ALOX5 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.